US20090137557A1 - Calcilytic Compounds - Google Patents

Calcilytic Compounds Download PDF

Info

Publication number
US20090137557A1
US20090137557A1 US12/094,665 US9466506A US2009137557A1 US 20090137557 A1 US20090137557 A1 US 20090137557A1 US 9466506 A US9466506 A US 9466506A US 2009137557 A1 US2009137557 A1 US 2009137557A1
Authority
US
United States
Prior art keywords
methyl
hydroxyphenyl
phenylethyl
pyrimidinone
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/094,665
Other languages
English (en)
Inventor
Thomas Wen Fu Ku
Hong Lin
Juan I. Luengo
Robert W. Marquis Jr.
Joshi M. Ramanjulu
Robert Trout
Dennis S. Yamashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to US12/094,665 priority Critical patent/US20090137557A1/en
Assigned to SMITHKLINE BEECHAM CORPORATION reassignment SMITHKLINE BEECHAM CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TROUT, ROBERT, KU, THOMAS WEN FU, LIN, HONG, LUENGO, JUAN I, MARQUIS, ROBERT W, JR, RAMANJULU, JOSHI M, YAMASHITA, DENNIS S
Publication of US20090137557A1 publication Critical patent/US20090137557A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Definitions

  • the present invention relates to novel calcilytic compounds, pharmaceutical compositions containing these compounds, processes for their preparation and their use as calcium receptor antagonists.
  • extracellular Ca 2+ In mammals, extracellular Ca 2+ is under rigid homeostatic control and regulates various processes such as blood clotting, nerve and muscle excitability, and proper bone formation. Extracellular Ca 2+ inhibits the secretion of parathyroid hormone (“PTH”) from parathyroid cells, inhibits bone resorption by osteoclasts, and stimulates secretion of calcitonin from C-cells. Calcium receptor proteins enable certain specialized cells to respond to changes in extracellular Ca 2+ concentration.
  • PTH parathyroid hormone
  • Calcium receptor proteins enable certain specialized cells to respond to changes in extracellular Ca 2+ concentration.
  • PTH is the principal endocrine factor regulating Ca 2+ homeostasis in the blood and extracellular fluids. PTH, by acting on bone and kidney cells, increases the level of Ca 2+ in the blood. This increase in extracellular Ca 2+ then acts as a negative feedback signal, depressing PTH secretion. The reciprocal relationship between extracellular Ca 2+ and PTH secretion forms an important mechanism maintaining bodily Ca 2+ homeostasis.
  • Extracellular Ca 2+ acts directly on parathyroid cells to regulate PTH secretion.
  • the existence of a parathyroid cell surface protein which detects changes in extracellular Ca 2+ has been confirmed. See Brown et al., Nature 366:574, 1993.
  • this protein the calcium receptor, acts as a receptor for extracellular Ca 2+ , detects changes in the ion concentration of extracellular Ca 2+ , and initiates a functional cellular response, PTH secretion.
  • extracellular Ca 2+ plays a role in parafollicular (C-cells) and parathyroid cells. See Nemeth, Cell Calcium 11:323, 1990.
  • the role of extracellular Ca 2+ on bone osteoclasts has also been studied. See Zaidi, Bioscience Reports 10:493, 1990.
  • Calcilytics are compounds able to inhibit calcium receptor activity, thereby causing a decrease in one or more calcium receptor activities evoked by extracellular Ca 2+ .
  • Calcilytics are useful as lead molecules in the discovery, development, design, modification and/or construction of useful calcium modulators, which are active at Ca 2+ receptors.
  • Such calcilytics are useful in the treatment of various disease states characterized by abnormal levels of one or more components, e.g., polypeptides such as hormones, enzymes or growth factors, the expression and/or secretion of which is regulated or affected by activity at one or more Ca 2+ receptors.
  • Target diseases or disorders for calcilytic compounds include diseases involving abnormal bone and mineral homeostasis.
  • Abnormal calcium homeostasis is characterized by one or more of the following activities: an abnormal increase or decrease in serum calcium; an abnormal increase or decrease in urinary excretion of calcium; an abnormal increase or decrease in bone calcium levels (for example, as assessed by bone mineral density measurements); an abnormal absorption of dietary calcium; an abnormal increase or decrease in the production and/or release of messengers which affect serum calcium levels such as PTH and calcitonin; and an abnormal change in the response elicited by messengers which affect serum calcium levels.
  • calcium receptor antagonists offer a unique approach towards the pharmacotherapy of diseases associated with abnormal bone or mineral homeostasis, such as hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia associated with malignancy and fracture healing, and osteoporosis.
  • the present invention comprises novel calcium receptor antagonists represented by Formula (I) and Formula (II) hereinbelow, formulations comprising the present compounds, and their use as calcium receptor antagonists in the treatment of a variety of diseases associated with abnormal bone or mineral homeostasis, including but not limited to hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia associated with malignancy and fracture healing, and osteoporosis.
  • diseases associated with abnormal bone or mineral homeostasis including but not limited to hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia associated with malignancy and fracture healing, and osteoporosis.
  • the present invention further provides a method for antagonizing calcium receptors in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of Formula (I) or (II), indicated hereinbelow.
  • the present invention further provides a method for increasing serum parathyroid levels in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of Formula (I) or (II), indicated hereinbelow.
  • the present invention involves novel compounds according to formula (I) hereinbelow:
  • X is O or S
  • R 1 and R 2 are, independently, selected from the group consisting of H, halogen, CN, C 1-10 alkyl, C 2-6 alkenyl, cycloalkyl, cycloalkylC 1-6 alkyl, aryl, arylC 1-6 alkyl, heterocyclyl, heteroaryl, (CR 10 R 11 ) x NR 5 R 6 , C(O)OR 5 , C(O)NR 5 R 6 , NR 5 C(O)R 6 , (CR 10 R 11 ) x OR 5 and NC(O)R 5 , optionally substituted, except for H, halogen and CN, one to three times, independently, by halogen, CN, C 1-4 alkyl, aryl, heteroaryl, C(O)OR 19 , O—(CR 19 R 20 ) q —O, C(O)R 19 , CF 3 , OCF 3 , NO 2 , C(O)NR 19 R 20 , (CR 10 R 11
  • R 1 and R 2 together form an optionally substituted 5 to 8 membered ring, optionally containing one to three heteroatoms selected from N, O and S, wherein the optional substituents are selected, independently, at each occurrence, one to three times, from the group consisting of halogen, C 1-4 alkyl, (CR 10 R 11 ) z S(O) m R 5 , (CR 10 R 11 ) z OR 5 , (CR 10 R 11 ) z NR 5 R 6 , C(O)R 5 and C(O)OR 5 ;
  • R 1 and R 2 together form an optionally substituted heteroaryl ring, wherein the optional substituents are selected, independently, at each occurrence, one to three times, from the group consisting of halogen, C 1-4 alkyl, (CR 10 R 11 ) z S(O) m R 5 , (CR 10 R 11 ) z OR 5 , (CR 10 R 11 ) z NR 5 R 6 , C(O)R 5 and C(O)OR 5 ;
  • R 1 is NR 5 R 6
  • R 5 and R 6 can join together to form a 5 to 7 membered ring, optionally substituted by C 1-4 alkyl or halogen;
  • R 5 and R 6 represent, independently, at each occurrence, H, C 1-4 alkyl, cycloalkyl, cycloalkylC 1-6 alkyl, C 2-6 alkenyl, heterocyclyl, heterocyclylC 1-6 alkyl, aryl, arylC 1-6 alkyl, heteroaryl or heteroarylC 1-6 alkyl, wherein each moiety, except H, is optionally substituted, independently, one to three times, by halogen or C 1-4 alkyl;
  • R 10 and R 11 represent, independently, at each occurrence, H or C 1-4 alkyl
  • R 19 and R 20 represent, independently, at each occurrence, H, C 1-4 alkyl, cycloalkyl, cycloalkylC 1-6 alkyl, C 2-6 alkenyl, heterocyclyl, heterocyclylC 1-4 alkyl, aryl, arylC 1-6 alkyl, heteroaryl or a heteroarylC 1-6 alkyl moiety, wherein each moiety, except H, may be substituted, independently, one to three times, by halogen or C 1-4 alkyl;
  • R 3 represents aryl or heteroaryl, optionally substituted, independently, one to three times, by C 1-4 alkyl, halogen, CN or CF 3 ;
  • R 4 is selected from the group consisting of cycloalkylC 1-4 alkyl, heteroaryl, heterocyclyl, aryl, heteroarylC 1-2 alkyl, heterocyclylC 1-2 alkyl, cycloalkylC 2 alkenyl, arylC 2 alkenyl, heteroarylC 2 alkenyl and heterocyclylC 2 alkenyl, wherein each moiety is optionally substituted, independently, one to three times, by C 1-4 alkyl, F, CF 3 or Cl;
  • n 0, 1 or 2;
  • x 0, 1, 2 or 3;
  • q 1, 2 or 3;
  • z 0, 1, 2, 3 or 4;
  • alkyl refers to a linear or branched saturated hydrocarbon group containing from 1 to 10 carbon atoms. Examples of such groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert butyl, n-pentyl, isopentyl, neopentyl or hexyl and the like.
  • cycloalkyl refers to a saturated monocyclic hydrocarbon ring of 3 to 7 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • heterocyclyl refers to a 4-8 membered monocyclic ring or a fused 8-12 membered bicyclic ring which may be saturated or partially unsaturated containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur.
  • monocyclic rings include pyrrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiazolidinyl, and the like.
  • heterocyclyl bicyclic rings examples include indolinyl, isoindolinyl, benzopyranyl, tetrahydrobenzazepinyl, tetrahydrobenzothienyl, tetrahydroisoquinolinyl and the like.
  • heterocyclylalkyl refers to a heterocyclyl-C 1-2 alkyl group, wherein heterocyclyl and C 1-2 alkyl are as defined herein.
  • aryl refers to a C 6 monocyclic or C 5-12 bicyclic hydrocarbon ring wherein at least one ring is aromatic. Examples of such groups include phenyl, naphthyl, indenyl or tetrahydronaphthyl and the like.
  • arylakyl refers to an aryl-C 1-6 alkyl group wherein aryl and C 1-6 alkyl are as defined herein.
  • heteroaryl refers to a 5-6 membered monocyclic aromatic or a fused 8-10 membered bicyclic aromatic ring containing 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur.
  • monocyclic aromatic rings include thienyl, furyl, furazanyl, pyrrolyl, thiazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl, pyridyl, and the like.
  • fused aromatic rings examples include isoquinolinyl, quinazolinyl, quinoxalinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, isobenzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, benzoisothiazolyl, and the like.
  • heteroarylalkyl refers to a heteroaryl-C 1-2 alkyl group wherein heteroaryl and C 1-2 alkyl are as defined herein.
  • alkenyl refers to a linear or branched hydrocarbon group containing one or more carbon-carbon double bonds having from 2 to 6 carbon atoms. Examples of such groups include ethenyl, propenyl, butenyl, pentenyl, or hexenyl and the like.
  • alkoxy refers to an —O—C 1-4 alkyl group wherein C 1-4 alkyl is as defined herein. Examples of such groups include methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy and the like.
  • halogen or “halo” refers to F, Cl, Br or I.
  • optionally substituted means substituted, independently, at each occurrence, one to three times, by such groups as halogen, CN, C 1-4 alkyl, C 2-4 alkenyl, cycloC 1-6 alkyl, heterocyclyl, aryl, heteroaryl, CO(O)R 5′ , O—(CH 2 ) n′ —O, C(O)R 5′ , CF 3 , OCF 3 , NO 2 , C(O)NR 5′ R 6′ , (CR 10′ R 11′ ) 2′ —OR 5′ , (CR 10′ R 11′ ) z′ NR 5′ R 6′ , and (CR 10′ R 11′ ) z′ S(O) m′ R 5′ such that the optional substituents may be further substituted, except for halogen and CN, one to three times, independently, by halogen or C 1-4 alkyl.
  • R 5′ and R 6′ represent, independently, at each occurrence, a H, C 1-3 alkyl, cycloalkyl, cycloalkylC 1-3 alkyl, C 2 alkenyl, heterocyclyl, heterocyclylC 1-4 alkyl, aryl, arylC 1-3 alkyl, heteroaryl or a heteroarylC 1-3 alkyl moiety, wherein each moiety, except H, is optionally substituted, independently, one to three times, by halogen or C 1-3 alkyl.
  • R 10′ and R 11′ represent, at each occurrence, independently, H or C 1-4 alkyl.
  • m′ is 0, 1 or 2.
  • n′ is 1, 2 or 3.
  • z′ is 0, 1, 2 or 3.
  • X is O or S.
  • X is O.
  • R 1 and R 2 are, independently, selected from the group consisting of H, halogen, —CN, C 1-10 alkyl, —C 2-6 alkenyl, cycloalkyl, cycloalkylC 1-6 alkyl, aryl, arylC 1-6 alkyl, heterocyclyl, heteroaryl, (CR 10 R 11 ) x NR 5 R 6 , C(O)OR 5 , C(O)NR 5 R 6 , NR 5 C(O)R 6 , (CR 10 R 11 ) x OR 5 and NC(O)R 5 , optionally substituted, except for H, halogen and CN, one to three times, independently, by halogen, CN, C 1-4 alkyl, aryl, heteroaryl, C(O)OR 19 , O—(CR 19 R 20 ) q —O, C(O)R 19 , CF 3 , OCF 3 , NO 2 , C(O)NR 19 R 20
  • R 1 and R 2 are, independently, selected from the group consisting of H, halogen, CN, C 1-10 alkyl, C 2-6 alkenyl, cycloC 1-4 alkyl, cycloalkylC 1-3 alkyl, aryl, arylC 1-3 alkyl, heterocyclyl, heteroaryl, (CR 10 R 11 ) x NR 5 R 6 , NH 2 , C(O)OR 5 , NR 5 C(O)C 1-4 alkyl, C 1-4 alkoxy, and (CR 10 R 11 ) x OR 5 , optionally substituted, one to three times, except for H, halogen and CN, independently, by halogen, CN, C 1-2 alkyl, aryl, heteroaryl, C(O)OR 19 , —O—(CH 2 ) q —O, C(O)R 19 , CF 3 , OCF 3 , NO 2 , C(O)NR 19 R 20 ,
  • R 1 and R 2 are, independently, selected from the group consisting of H, halogen, CN, C 2-3 alkenyl, C(O)OH, phenethyl, pyrrolidinyl, N-propyl, NHC(O)C 1-3 alkyl and C(O)CH 3 .
  • R 1 and R 2 are, independently, selected from the group consisting of a C 1-6 alkyl, C 3-5 cycloalkyl and C 3-4 cycloalkylC 1-2 alkyl, wherein each moiety is optionally substituted, independently, one to three times, by C 1-2 alkyl or halogen.
  • R 1 and R 2 represent, independently, phenyl, optionally substituted, independently, one to three times, by an optional substituent selected from the group consisting of F, OH, methyl, CN, OCF 3 , CF 3 , NH 2 , CH 2 OH, N-dimethyl, ethoxy, phenyl, NO 2 , methylsulfonyl, isopropoxy and CH 2 NC 1-2 alkyl.
  • R 1 and R 2 represent, independently, piperidinyl, optionally substituted by C 1-3 alkyl.
  • R 1 and R 2 represent, independently, an amine moiety, optionally substituted by C 1-4 alkyl.
  • R 1 and R 2 represent, independently, an ether moiety, substituted by C 1-3 alkyl or benzyl.
  • R 1 and R 2 represent, independently, a heteroaryl moiety selected from the group consisting of furyl, pyrizinyl, pyridyl, indanyl, thienyl, pyrrolyl, and thiazolyl, wherein the heteroaryl moiety is optionally substituted, independently, once or twice, by a substituent selected from the group consisting of methyl, chloro, CH 2 NH 2 , CN, CH 2 OH, phenyl, CH 2 NHCH 3 and 1,3,4-oxadiazolyl.
  • R 1 and R 2 represent, independently, a heterocyclyl bicyclic moiety selected from the group consisting of quinolinyl, tetrahydroquinolinyl, methyltetrahydroquinolinyl, dihydrobenzodioxinyl, 3-benzothiophenyl, benzodioxolyl, benzothienyl, benzothiophenyl, benzofuranyl, indolyl, and thiazolyl, wherein the bicyclic moiety may be optionally substituted, independently, one to three times, by a substituent selected from the group consisting of methyl, phenyl, chloro and thiazolyl.
  • R 1 and R 2 are selected, independently from the group consisting of hydrogen, I, Cl, Br, F, ON, methyl, ethyl, isobutyl, propyl, butyl, isopropyl, hexyl, 2-methylbutyl, 3-methylbutyl, 2-hydroxyethyl, 2-methyl-2-propenyl, 2-methyl-1-propenyl, 1-propenyl, cyclopentyl, cyclopropyl, cyclobutylethyl, cyclobutylmethyl, cyclopropylmethyl, phenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-methylphenyl, 4-hydroxyphenyl, 2-cyanophenyl, 4-cyanophenyl, 4-trifluoromethylphenyl, 3-hydroxymethylphenyl, 3-hydroxyphenyl, 4-N,N,N
  • R 1 is selected from the group consisting of isobutyl, ethyl, phenyl, furanyl, quinolinyl, halogen, tetrahydroquinolinyl, pyrrolidinyl, thiophenyl, morpholinyl, cyclopentyl, isopropyl, amino, pyrazinyl, indolyl, thiazolyl, piperidinyl, N-acyl, benzothiophenyl and benzothiazolyl, all of which moieties may be optionally substituted, independently, one to three times, by C 1-4 -alkyl or halogen.
  • R 1 is selected from the group consisting of isobutyl, phenyl, thiazolyl and thienyl, optionally substituted by methyl.
  • R 2 is selected from the group consisting of methyl, methoxymethyl, piperidinyl, ethyl, methoxyethyl, benzyloxyethyl, phenyl, pyrrolidinyl, amino, alkylamino, propyl, phenethyl, phenpropyl, butyl, isobutyl, cyclobutylethyl, 3-methylbutyl, dimethylaminomethyl, piperidinylmethyl, and alkylaminomethyl, all of which moieties may be optionally substituted, independently, one to three times, by C 1-4 alkyl or halogen.
  • R 2 is methyl, ethyl or propyl.
  • R 2 is methyl
  • R 1 and R 2 together form an optionally substituted 5 to 8 membered ring, optionally containing one to three heteroatoms selected from N, O and S, wherein the optional substituents are selected, independently, at each occurrence, one to three times, from the group consisting of halogen, C 1-4 alkyl, (CR 10 R 11 ) z S(O) m R 5 , (CR 10 R 11 ) z OR 5 , (CR 10 R 11 ) z NR 5 R 6 , C(O)R 5 and C(O)OR 5 .
  • R 1 and R 2 together form an optionally substituted heteroaryl ring, wherein the optional substituents are selected, independently, at each occurrence, one to three times, from the group consisting of halogen, C 1-4 alkyl, (CR 10 R 11 ) z S(O) m R 5 , (CR 10 R 11 ) z OR 5 , (CR 10 R 11 ) z NR 5 R 6 , C(O)R 5 and C(O)OR 5 .
  • R 1 is NR 5 R 6
  • R 5 and R 6 join together to form a 5 to 7 membered ring, optionally substituted by C 1-4 alkyl or halogen.
  • R 1 and R 2 combine to form, together with the adjacent ring, a moiety selected from the group consisting of pyrimidinonyl, quinazolinyl, pyrridolpyrimidinecarboxylyl, pyrimidoazepinyl, cyclooctapyrimidinonyl, tetrahydropyrrolopyrimidinecarboxylyl, and pyrrazolopyrimidinonyl, optionally substituted, independently, once or twice, by a substituent selected from the group consisting of methyl, ethyl, benzyl, acetyl, methylsulfonyl, COCH 2 C(CH 3 ) 2 and C(O)OCH 2 C(CH 3 ) 2 .
  • R 1 and R 2 combine to form, together with the adjacent ring, a moiety selected from the group consisting of azepinyl, cyclohexyl, cycloheptyl, tetrahydrooxepinyl, tetrahydropyridynyl, tetrahydropyrrolidinyl, pyrazolyl and cyclooctyl, all of which moieties may be optionally substituted, independently, one to three times, by C 1-4 alkyl or halogen.
  • R 1 and R 2 combine to form, along with the adjacent ring, a moiety selected from the group consisting of 6-phenylmethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-onyl, 5,6,7,8-tetrahydro-4(3H)-quinazolinonyl, 6,6-dimethyl-4a,5,6,7,8,8a-hexahydro-4(3H)-quinazolinonyl, 3,5,6,7,8,9-hexahydrocycloheptapyrimidin-4-onyl, ethyl 3,5,7,8-tetrahydropyridolpyrimidine-6-carboxylyl, 3,5,6,7,8,9-hexahydropyrimido-4,5-azepin-4-onyl, 7-benzyl-3,5,6,7,8,9-hexahydropyrimido-4,5-azepin-4-onyl, 7
  • the ring is cyclohexyl or dimethylcyclohexyl.
  • R 3 represents aryl or heteroaryl, optionally substituted, independently, one to three times, by C 1-4 alkyl, halogen, CN or CF 3 .
  • R 3 represents an aryl or heteroaryl moiety, optionally substituted, independently, one to three times, by a substituent selected from F, OH and Cl.
  • R 3 is selected from the group consisting of phenyl, pyrrolyl, thienyl, pyrridolyl, furanyl, imidazolyl, and furyl, optionally substituted, independently, once or twice, with a substituent selected from the group consisting of OH, F, methoxy and OCH 2 phenyl.
  • R 3 is selected from the group consisting of 2-hydroxy-4-fluorophenyl, 2-hydroxy-3-fluorophenyl, 3-hydroxy-2-fluorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 2,3-dihydroxyphenyl, 2-fluorophenyl, 2-hydroxy-3-fluorophenyl, 2-methoxyphenyl, 3-fluoro-2(phenylmethyl)oxyphenyl, 2-pyrrolyl, 2-thienyl, 2-pyrridolyl, 2-furanyl, 2-imidazolyl, 2-furyl, and thienyl.
  • R 4 is selected from the group consisting of cycloalkyl 1-4 alkyl, heteroaryl, heterocyclyl, aryl, heteroarylC 1-2 alkyl, heterocyclylC 1-2 alkyl, cycloalkylC 2 alkenyl, arylC 2 alkenyl, heteroarylC 2 alkenyl and heterocyclylC 2 alkenyl, wherein each moiety is optionally substituted, independently, one to three times, by C 1-4 alkyl, F, CF 3 or Cl.
  • R 4 is selected from the group consisting of phenylC 1-2 alkyl, cyclohexylC 1-2 alkyl, cyclopentylC 1-2 alkyl, thienylC 1-2 alkyl, pyranylC 1-2 alkyl, indenylC 1-2 alkyl and piperidinylC 1-2 alkyl, optionally substituted, independently, once or twice, by F, CF 3 or Cl.
  • R 4 is selected from the group consisting of phenylC 2 alkenyl, cyclohexylC 2 alkenyl, cyclopentylC 2 alkenyl, thienylC 2 alkenyl, pyranylC 2 alkenyl, indenylC 2 alkenyl and indenylC 2 alkenyl.
  • R 4 is selected from the group consisting of 3-fluorophenylC 1-2 alkyl, phenylC 1-2 alkyl, 2-fluorophenylC 1-2 alkyl, 3-trifluoromethylphenylC 1-2 alkyl, 2-chlorophenylC 1-2 alkyl, cyclopentylC 1-2 alkyl, cyclohexylC 1-2 alkyl, 2-thienylC 1-2 alkyl, 3-thienylC 1-2 alkyl, pyranylC 1-2 alkyl, indenylC 1-2 alkyl and piperidinylC 1-2 alkyl.
  • R 4 is selected from the group consisting of phenethyl, 3-fluorophenethyl, 4-fluorophenethyl, 2-fluorophenethyl, 2-thienylethyl, phenylethyl, dihydroindenyl, cyclohexylethyl, 3-chlorophenethyl, 3-trifluoromethylphenethyl, cyclopentylethyl and tetrahydropyranylethyl.
  • R 4 is phenethyl, optionally substituted, once or twice, independently, by F.
  • R 10 and R 11 represent, independently, hydrogen or C 1-4 alkyl.
  • O—(CR 5 R 6 ) q —O represents 1,3-benzodioxinyl or 1,4-benzodioxinyl.
  • q is 2 or 3.
  • R 1 and R 2 are, independently, selected from the group consisting of H, halogen, C 1-8 alkyl, aryl, heterocyclyl, and heteroaryl, optionally substituted, except for H, and halogen, one to three times, independently, by halogen, ON, C 1-4 alkyl, aryl, heteroaryl, —O—(CH 2 ) n —O, CF 3 , and OCF 3 ;
  • R 1 and R 2 together form a 5 to 8 membered ring, optionally containing one to three heteroatoms selected from N, O and S, optionally substituted, independently, once or twice, by methyl;
  • R 14 represents F or H
  • R 4 is represents arylC 1-2 alkyl, optionally substituted, independently, one to three times, by F, CF 3 or Cl;
  • n 1, 2, or 3;
  • R 1 and R 2 are, independently, selected from the group consisting of H, halogen, C 1-8 alkyl, aryl, heterocyclyl, and heteroaryl, optionally substituted, except for H, and halogen, one to three times, independently, by halogen, CN, C 1-4 alkyl, aryl, heteroaryl, —O—(CH 2 ) n —O, CF 3 , and OCF 3 .
  • R 1 is selected from the group consisting of C 1-4 alkyl, halogen, dihydrobenzodioxy, N-pyrrolyl, benzothienyl, benzothiazolyl.
  • R 1 represents phenyl, optionally substituted, independently, once or twice, by F, Cl, and ON.
  • R 1 represents thienyl, optionally substituted, independently, once or twice, by F, methyl, or ON.
  • R 1 represents thiazolyl, optionally substituted by methyl.
  • R 1 is selected from the group consisting of chloro, propyl, isobutyl, 2-thienyl, 5-methyl-2-thienyl, 3-cyano-2-thienyl, 4-methyl-2-thienyl, 3-cyano-2-thienyl, 2-cyanophenyl, 3-cyanophenyl, 3,5-difluorophenyl, dihydrobenzodioxyl, benzothienyl, benzothiazolyl, 2-methylthiazolyl, N-pyrrolyl and 2-methylthiazolyl.
  • R 1 is selected from the group consisting of isobutyl, thienyl, 4-methyl-2-thienyl, phenyl and thiazolyl.
  • R 1 and R 2 together form a 5 to 8 membered ring, optionally containing one to three heteroatoms selected from N, O and S, optionally substituted, independently, once or twice, by methyl.
  • the ring is selected from the group consisting of cyclohexyl and dimethylcyclohexyl.
  • R 2 is methyl, ethyl or propyl.
  • R 2 is methyl
  • R 14 represents F or H.
  • R 14 is F.
  • R 4 is represents arylC 1-2 alkyl, optionally substituted, independently, one to three times, by F, CF 3 or Cl.
  • R 4 is phenethyl, optionally substituted by F.
  • R 4 is 3-fluorophenethyl.
  • n 1, 2 or 3.
  • n 1 or 2.
  • Preferred compounds of the present invention include but are not limited to:
  • More preferred compounds useful in the present invention include but are not limited to:
  • salts and solvates of compounds of the invention which are suitable for use in medicine are those wherein the counterion or associated solvent is pharmaceutically acceptable.
  • salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of the invention and their pharmaceutically acceptable salts and solvates.
  • the present compounds may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof.
  • crystalline forms of the present compounds may exist as polymorphs, which are included in the present invention.
  • salts of the compounds of formula (I) and (II) are preferably pharmaceutically acceptable.
  • Suitable pharmaceutically acceptable salts can include acid or base addition salts.
  • a pharmaceutically acceptable acid addition salt can be formed by reaction of a compound of formula (I) or (II) with a suitable inorganic or organic acid (such as hydrobromic, hydrochloric, sulfuric, nitric, phosphoric, succinic, maleic, formic, acetic, propionic, fumaric, citric, tartaric, lactic, benzoic, salicylic, glutamaic, aspartic, p-toluenesulfonic, benzenesulfonic, methanesulfonic, ethanesulfonic, naphthalenesulfonic such as 2-naphthalenesulfonic, or hexanoic acid), optionally in a suitable solvent such as an organic solvent, to give the salt which is usually isolated for example by crystallisation and filtration.
  • a suitable inorganic or organic acid such as hydrobromic, hydrochloric, sulfuric, nitric, phosphoric, succinic, maleic, formic
  • a pharmaceutically acceptable acid addition salt of a compound of formula (I) or (II) can comprise or be for example a hydrobromide, hydrochloride, sulfate, nitrate, phosphate, succinate, maleate, formate, acetate, propionate, fumarate, citrate, tartrate, lactate, benzoate, salicylate, glutamate, aspartate, p-toluenesulfonate, benzenesulfonate, methanesulfonate, ethanesulfonate, naphthalenesulfonate (e.g. 2-naphthalenesulfonate) or hexanoate salt.
  • a hydrobromide hydrochloride, sulfate, nitrate, phosphate, succinate, maleate, formate, acetate, propionate, fumarate, citrate, tartrate, lactate, benzoate, salicylate, glutamate, aspartate,
  • a pharmaceutically acceptable base addition salt can be formed by reaction of a compound of formula (I) or (II) with a suitable inorganic or organic base (e.g. triethylamine, ethanolamine, triethanolamine, choline, arginine, lysine or histidine), optionally in a suitable solvent such as an organic solvent, to give the base addition salt which is usually isolated for example by crystallisation and filtration.
  • a suitable inorganic or organic base e.g. triethylamine, ethanolamine, triethanolamine, choline, arginine, lysine or histidine
  • a suitable solvent such as an organic solvent
  • compositions include pharmaceutically acceptable metal salts, for example pharmaceutically acceptable alkali-metal or alkaline-earth-metal salts such as sodium, potassium, calcium or magnesium salts; in particular pharmaceutically acceptable metal salts of one or more carboxylic acid moieties that may be present in the compound of formula (I) or (II).
  • pharmaceutically acceptable metal salts for example pharmaceutically acceptable alkali-metal or alkaline-earth-metal salts such as sodium, potassium, calcium or magnesium salts; in particular pharmaceutically acceptable metal salts of one or more carboxylic acid moieties that may be present in the compound of formula (I) or (II).
  • non-pharmaceutically acceptable salts e.g. oxalates
  • oxalates may be used, for example in the isolation of compounds of the invention, and are included within the scope of this invention.
  • the invention includes within its scope all possible stoichiometric and non-stoichiometric forms of the salts of the compounds of formula (I) or (II).
  • R 18 represents a C 1-2 alkyl, benzyl or acetyl protecting group in Scheme 3.
  • Y is a displacing group selected from F, Cl, Br and I.
  • R 4 is selected from the group consisting of phenethyl, 3-fluorophenethyl, 4-fluorophenethyl, 2-fluorophenethyl, 2-thienyl ethyl, phenylethyl, dihydroindenyl, cyclohexylethyl, 3-chlorophenethyl, 3-trifluoromethylphenethyl, cyclopentyl ethyl and tetrahydropyranylethyl.
  • Scheme 3 discloses a novel method of converting an enamide according to 7 to a pyrimidinone according to 8. Novel intermediates include compounds 7, 8, 9 and 10 in Scheme 3.
  • ⁇ acute over ( ⁇ ) ⁇ -Substituted- ⁇ -keto-amides such as 14 can be prepared by a microwave-assisted thermal addition of an amine to a ⁇ -keto-ester such as 13.
  • the enol triflate 15 is formed under conditions common to the art such as trifluoromethanesulfonic acid anhydride in the presence of a base such as triethyl amine. Subsequent treatment of the enol triflate 15 with a benzamide in the presence of a palladium catalyst and inorganic base such as cesium carbonate provides the enamide 16. Standard conditions common to the art are utilized to affect cyclization to the fully functionalized pyrimidinone 17.
  • the calcilytic compounds can be administered by different routes including intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical (transdermal), or transmucosal administration.
  • oral administration is preferred.
  • the compounds can be formulated into conventional oral dosage forms such as capsules, tablets, and liquid preparations such as syrups, elixirs, and concentrated drops.
  • injection parenteral administration
  • the compounds of the invention are formulated in liquid solutions, preferably, in physiologically compatible buffers or solutions, such as saline solution, Hank's solution, or Ringer's solution.
  • the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives.
  • detergents may be used to facilitate permeation.
  • Transmucosal administration for example, may be through nasal sprays, rectal suppositories, or vaginal suppositories.
  • the compounds of the invention can be formulated into ointments, salves, gels, or creams, as is generally known in the art.
  • the amounts of various calcilytic compounds to be administered can be determined by standard procedures taking into account factors such as the compound IC 50 , EC 50 , the biological half-life of the compound, the age, size and weight of the patient, and the disease or disorder associated with the patient. The importance of these and other factors to be considered are known to those of ordinary skill in the art.
  • Amounts administered also depend on the routes of administration and the degree of oral bioavailability. For example, for compounds with low oral bioavailability, relatively higher doses will have to be administered.
  • the composition is in unit dosage form.
  • a tablet, or capsule may be administered, for nasal application, a metered aerosol dose may be administered, for transdermal application, a topical formulation or patch may be administered and for transmucosal delivery, a buccal patch may be administered.
  • dosing is such that the patient may administer a single dose.
  • Each dosage unit for oral administration contains suitably from 0.01 to 500 mg/Kg, and preferably from 0.1 to 50 mg/Kg, of a compound of Formula (I) or (II) or a pharmaceutically acceptable salt thereof, calculated as the free base.
  • the daily dosage for parenteral, nasal, oral inhalation, transmucosal or transdermal routes contains suitably from 0.01 mg to 100 mg/Kg, of a compound of Formula (I) or (II).
  • a topical formulation contains suitably 0.01 to 5.0% of a compound of Formula (I) or (II).
  • the active ingredient may be administered, for example, from 1 to 6 times per day, preferably once, sufficient to exhibit the desired activity, as is readily apparent to one skilled in the art.
  • treatment includes, but is not limited to prevention, retardation and prophylaxis of the disease.
  • Diseases and disorders which might be treated or prevented, based upon the affected cells include bone and mineral-related diseases or disorders; hypoparathyroidism; those of the central nervous system such as seizures, stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage, such as occurs in cardiac arrest or neonatal distress, epilepsy, neurodegenerative diseases such as Alzheimer's disease, Huntington's disease and Parkinson's disease, dementia, muscle tension, depression, anxiety, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, schizophrenia, neuroleptic malignant syndrome, and Tourette's syndrome; diseases involving excess water reabsorption by the kidney, such as syndrome of inappropriate ADH secretion (SIADH), cirrhosis, congestive heart failure, and nephrosis; hypertension; preventing and/or decreasing renal toxicity from cationic antibiotics (e.g., aminoglycoside antibiotics); gut motility disorders such as diarrhea and spastic colon; GI ulcer diseases; GI diseases with excessive calcium absorption such as s
  • the present compounds are used to increase serum parathyroid hormone (“PTH”) levels.
  • PTH serum parathyroid hormone
  • Increasing serum PTH levels can be helpful in treating diseases such as hypoparathyroidism, osteosarcoma, periodontal disease, fracture, osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia malignancy and osteoporosis.
  • Another aspect of the present invention describes a method of treating a patient comprising administering to the patient an amount of a present compound sufficient to increase the serum PTH level.
  • the method is carried out by administering an amount of the compound effective to cause an increase in duration and/or quantity of serum PTH level sufficient to have a therapeutic effect.
  • the compound administered to a patient causes an increase in serum PTH having a duration of up to one hour, about one to about twenty-four hours, about one to about twelve hours, about one to about six hours, about one to about five hours, about one to about four hours, about two to about five hours, about two to about four hours, or about three to about six hours.
  • the compound administered to a patient causes an increase in serum PTH having a duration of more than about twenty-four hours provided that it is co-administered with an anti resorptive agent.
  • the compound administered to a patient causes an increase in serum PTH of up to two fold, two to five fold, five to ten fold, and at least 10 fold, greater than peak serum PTH in the patient.
  • the peak serum level is measured with respect to a patient not undergoing treatment.
  • the present compound is co-administered with an anti-resorptive agent.
  • Suitable anti-resorptive agents for co-administration include, but are not limited to estrogen, 1 ⁇ ,25-(OH) 2 D 3 , 1 ⁇ -(OH)D 3 , calcitonin, selective estrogen receptor modulators, vitronectin receptor antagonists, V-H+-ATPase inhibitors, src SH 2 antagonists, bisphosphonates and cathepsin K inhibitors.
  • Composition of Formula (I) or (II) and their pharmaceutically acceptable salts, which are active when given orally, can be formulated as syrups, tablets, capsules and lozenges.
  • a syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent.
  • a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent.
  • any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose.
  • composition is in the form of a capsule
  • any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell.
  • composition is in the form of a soft gelatin shell capsule
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.
  • Typical parenteral compositions consist of a solution or suspension of a compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • a parenterally acceptable oil for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.
  • a typical suppository formulation comprises a compound of Formula (I) or (II) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs.
  • a binding and/or lubricating agent for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs.
  • Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose.
  • Calcilytic activity was measured by determining the IC 50 of the test compound for blocking increases of intracellular Ca 2+ elicited by extracellular Ca 2+ in HEK 293 4.0-7 cells stably expressing the human calcium receptor.
  • HEK 293 4.0-7 cells were constructed as described by Rogers et al., J. Bone Miner. Res. 10 Suppl. 1:3483, 1995 (hereby incorporated by reference herein).
  • Intracellular Ca 2+ increases were elicited by increasing extracellular Ca 2+ from 1 to 1.75 mM.
  • Intracellular Ca 2+ was measured using fluo-3, a fluorescent calcium indicator.
  • Cells were maintained in T-150 flasks in selection media (DMEM supplemented with 10% fetal bovine serum and 200 ug/mL hygromycin B), under 5% CO 2 :95% air at 37° C. and were grown up to 90% confluency.
  • selection media DMEM supplemented with 10% fetal bovine serum and 200 ug/mL hygromycin B
  • the medium was decanted and the cell monolayer was washed twice with phosphate-buffered saline (PBS) kept at 37° C. After the second wash, 6 mL of 0.02% EDTA in PBS was added and incubated for 4 minutes at 37° C. Following the incubation, cells were dispersed by gentle agitation.
  • PBS phosphate-buffered saline
  • Sulfate- and phosphate-free parathyroid cell buffer contains 20 mM Na-Hepes, pH 7.4, 126 mM NaCl, 5 mM KCl, and 1 mM MgCl 2 .
  • SPF-PCB was made up and stored at 4° C. On the day of use, SPF-PCB was supplemented with 1 mg/mL of D-glucose and 1 mM CaCl 2 and then split into two fractions. To one fraction, bovine serum albumin (BSA; fraction V, ICN) was added at 5 mg/mL (SPF-PCB+). This buffer was used for washing, loading and maintaining the cells. The BSA-free fraction was used for diluting the cells in the cuvette for measurements of fluorescence.
  • BSA bovine serum albumin
  • the pellet was resuspended in 10 mL of SPF-PCB+ containing 2.2 uM fluo-3 (Molecular Probes) and incubated at room temperature for 35 minutes.
  • test compound or vehicle as a control
  • Calcilytic compounds were detected by their ability to block, in a concentration-dependent manner, increases in the concentration of intracellular Ca 2+ elicited by extracellular Ca 2+ .
  • those compounds having lower IC 50 values in the Calcium Receptor Inhibitor Assay are more preferred compounds.
  • Compounds having an IC 50 greater than 30 uM were considered to be inactive.
  • Preferred compounds are those having an IC 50 of 10 uM or lower.
  • the present examples were tested except for Examples 11, 20, 28, 44 and 107. All compounds tested were found to be active, except for Examples 27, 46, 100, 123, 127, 214, 215 and 216 at the concentrations used.
  • HEK 293 4.0-7 cells stably transfected with the Human Parathyroid Calcium Receptor (“HuPaR”) were scaled up in T180 tissue culture flasks.
  • Plasma membrane is obtained by polytron homogenization or glass douncing in buffer (50 mM Tris-HCl pH 7.4, 1 mM EDTA, 3 mM MgCl 2 ) in the presence of a protease inhibitor cocktail containing 1 uM Leupeptin, 0.04 uM Pepstatin, and 1 mM PMSF. Aliquoted membrane was snap frozen and stored at ⁇ 80° C. 3 H labeled compound was radiolabeled to a radiospecific activity of 44 Ci/mmole and was aliquoted and stored in liquid nitrogen for radiochemical stability.
  • a typical reaction mixture contains 2 nM 3 H compound ((R,R)—N-4′-Methoxy-t-3-3′methyl-1′-ethylphenyl-1-(1-naphthyl)ethylamine), or 3 H compound (R)—N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-1,1-dimethyl-2-(4-methoxyphenyl)ethylamine 4-10 ug membrane in homogenization buffer containing 0.1% gelatin and 10% EtOH in a reaction volume of 0.5 mL. Incubation is performed in 12 ⁇ 75 polyethylene tubes in an ice water bath.
  • the binding reaction is terminated by rapid filtration onto 1% PEI pretreated GF/C filters using a Brandel Harvestor. Filters are placed in scintillation fluid and radioactivity assessed by liquid scintillation counting. Preferred compounds are those having an IC 50 of 10 uM or lower. The present examples were tested except for Examples 11, 20, 28, 44 and 107. All compounds tested were found to be active.
  • the animals male beagle dogs
  • the animals were fed a diet of “Certified Canine Diet” #5007, approximately 300-500 grams per day. Water was provided ad libitum. During dosing days, animals were fasted (no morning feeding), and the animals were fed after the 240 minute blood collection time point.
  • All animals were dosed via oral gavage using a 24 french feeding tube attached to a three way stop cock. After introduction of the feeding tube into the stomach, approximately 10 mL of a 20 mL water flush was gavaged to ensure proper placement of the dosing tube. Dose was then administered at Xmg [6 ml]/kg. Following dose administration the remainder of water flush (approximately 10 mL) was gavaged to clear out the dosing tube.
  • Blood samples (approximately 3 mL) were obtained from either a cephalic or saphenous vein using 20 gauge catheter and injection cap or a 23 gauge needle and syringe. The catheter was locked with a heparin glucose lock (prepared by the LAS department) between samples. Blood samples were obtained just prior to dosing and at 5, 10, 15, 30, 60, 90, 120, 240 and 360 minutes post dose. The whole blood was placed in a sodium heparinized vacutainer tube and slightly vortexed to inhibit clotting and properly mix the sample. From each sample collected, a 100 ⁇ L aliquot was used to determine blood ionized calcium using the Medica Easylyte calcium analyzer.
  • a 25 ⁇ L blood sample was immediately transferred to an appropriately labelled tube. Nanopure water (25 ⁇ L) was added to this tube and then vortexed (this was done in duplicate). This sample was allowed to sit for approximately 0.5 min at room temperature to allow for blood cell lysis, and then placed on dry ice. Concentrations of compounds were quantified by HPLC/MS/MS by the DMPK MMPD CEDD department. An aliqout of whole blood ( ⁇ 200 ⁇ L) and approximately 5 mg of compound was quantified. The remainder of whole blood was centrifuged and plasma separated for determination of PTH1-84.
  • Nuclear magnetic resonance spectra were recorded at either 300 or 400 MHz using, respectively, a Bruker ARX 300 or Bruker AVANCE 400 spectrometer.
  • CDCl 3 is deuteriochloroform
  • DMSO-d 6 is hexadeuteriodimethylsulfoxide
  • CD 3 OD is tetradeuteriomethanol. Chemical shifts are reported in parts per million ( ⁇ ) downfield from the internal standard tetramethylsilane.
  • ODS refers to an octadecylsilyl derivatized silica gel chromatographic support.
  • 5 ⁇ Apex-ODS indicates an octadecylsilyl derivatized silica gel chromatographic support having a nominal particle size of 5 ⁇ , made by Jones Chromatography, Littleton, Colo.
  • YMC ODS-AQ® is an ODS chromatographic support and is a registered trademark of YMC Co. Ltd., Kyoto, Japan.
  • PRP-1® is a polymeric (styrene-divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nev.)
  • Celite® is a filter aid composed of acid-washed diatomaceous silica, and is a registered trademark of Manville Corporation, Denver, Colo.
  • Example 9d Ethyl-N-[2-(3-fluorophenyl)ethyl]-3-oxobutanamide (0.5 g, 2.14 mmol) of Example 9d was taken up in titanium isopropoxide (2.78 mmol, 8.5 mL). To this was added 1H-pyrrole-2-carboxamide (0.35 g, 3.21 mmol), and reaction was heated to reflux for 48 h. Upon completion, the reaction was diluted with dichloromethane and washed with 3N HCl.
  • the hydroxy acid (10 g, 0.064 moles) was taken up in anhydrous methanol (215 mL). To this was added catalytic amount of sulfuric acid and the reaction was reflux for 16 h. The reaction was concentrated and the crude product was taken into the next step without purification.
  • the methyl ester was placed in pressure reaction vessel. To this was added 2N ammonia in methanol (125 mL) and the reaction was heated to 110° C. for 16 h. The reaction was concentrated and taken up in dichloromethane. The undissolved material is filtered off. The reaction is concentrated and dissolved in large amount of methanol and was decolorized. The methanol solution was partly concentrated upon which crystalline solid (pale brown) was crashed out. The solid is filtered and used in the next step.
  • reaction mixture was filtered through syringe filter (Acrodisc CR25 mm with 0.20 ⁇ m PTFE membrane). The filtrate was diluted with EtOAc and washed with brine, separated, dried over sodium sulfate, filtered, concentrated in vacuo and the residue was purified by chromatography on silica gel (Biotage, 0-60% ethyl acetate/hexane) to afford the desired product (0.12 g) in 66% yield. MS (m/z): 452.4 [M+H] + .
  • Example 14 To a solution of Example 14 (0.02 g, 0.044 mol) in methanol was added formaldehyde (0.018 mL, 0.66 mmol) and NaCNBH 3 (8.15 mg, 0.13 mmole) sequentially. Reaction was stirred for 48 h at ambient temperature. The reaction mixture was concentrated and diluted with dichloromethane and washed with water and brine. The organic layer was separated dried over sodium sulphate, filtered and concentrated. The residue was purified by reverse phase HPLC to afford the desired product (7 mg) in 34% yield. MS (m/z): 470.2 [M+H] + .
  • the crude residue is diluted with dichloromethane and washed with saturated aqueous potassium fluoride, water and brine. The organic layer was separated, dried over Na 2 SO 4 , filtered and concentrated. The crude material was purified by chromatography on silica gel (Biotage, 0-50% ethyl acetate/hexane) to afford the desired product (0.81 g) in 81% yield.
  • the reaction mixture was concentrated and purified by chromatography on silica gel (Biotage) using EtOAc and hexane mixtures (5-30%) to obtain the desired product (0.32 g) which contained small amount of impurity.
  • Methyl-3-(2-phenylethyl)-2- ⁇ 2-[(phenylmethyl)oxy]phenyl ⁇ -4(3H)-pyrimidinone was prepared according to the procedures described in Example 11d except 3-fluoro-2-hydroxybenzamide was replaced with 2-hydroxybenzamide.
  • Methyl-3-(2-phenylethyl)-2- ⁇ 2-[(phenylmethyl)oxy]phenyl ⁇ -4(3H)-pyrimidinone (4.23 g, 10.7 mmoles) was taken up in glacial acetic acid (107 mL). To this was added 1M dichloromethane solution of iodine monochloride (31 mL, 32.1 mmoles) and the reaction was stirred for 16 h. Ethyl acetate was added and acetic acid was washed with saturated sodium carbonate. The organic layer dried over sodium sulfate. Sodium sulfate was filtered off and organic layer was concentrated. The crude product was purified by chromatography on silica gel (Biotage) using ethyl acetate and hexane mixtures (20-50%) to obtain the desired product (2.5 g) in 45% yield.
  • the reaction mixture was diluted with EtOAc and washed with H 2 O, brine and dried (Na 2 SO 4 ) and concentrated.
  • the crude product was purified by flash column chromatography (30% EtOAc/hexane) to afford the desired product (0.081 g) in 47% yield.
  • This compound was prepared by following the general procedures outlined in Example 27 and substituting methyl iodide in place of benzyl bromide in step 1a.
  • Example 38 6-[(Methyloxy)methyl]-3-(2-phenylethyl)-2-[2-[(phenylmethyl)oxy]phenyl]-4(3H)-pyrimidinone (0.8 g, 1.9 mmol) of Example 38 was taken up in glacial acetic acid. To this was added bromine (0.144 mL, 2.8 mmol) dropwise by a syringe. Reaction was stirred for 16 h. Ethyl acetate was added and acetic acid was washed with saturated sodium bicarbonate. The organic layer was further washed with saturated solution of sodium hydrogensulfite/sodium metabisulfite and dried over sodium sulfate. Sodium sulfate was filtered off and organic layer was concentrated. The crude product was purified by chromatography on silica gel (Biotage) to obtain the desired product.
  • reaction mixture was filtered through syringe filter (Acrodisc CR25 mm-with-0.2 ⁇ m PTFE membrane).
  • the filtrate was diluted with EtOAc and washed with brine, separated, dried over sodium sulfate, filtered, concentrated in vacuo and the residue was purified by chromatography on silica gel (Biotage, 0-60% ethyl acetate/hexane) to afford the desired product (0.86 g) in 64% yield.
  • 6-Methyl-2-[2-(methyloxy)phenyl]-3-(2-phenylethyl)-4(3H)-pyrimidinone (0.21 g, 0.66 mmoles) was taken up in glacial acetic acid (13 mL). To this was added 1M dichloromethane solution of iodine monochloride (0.72 mL, 0.72 mmoles) and the reaction was stirred for 16 h. Ethyl acetate was added and acetic acid was washed with saturated sodium carbonate. The organic layer dried over sodium sulfate. Sodium sulfate was filtered off and organic layer was concentrated.
  • Example 20 To a solution of 5-bromo-6-methyl-3-(2-phenylethyl)-2- ⁇ 2-[(phenylmethyl)oxy]phenyl ⁇ -4(3H)-pyrimidinone (0.10 g, 0.21 mmoles) of Example 20 in dioxane (5 mL) was added aniline (0.027 g, 0.30 mmoles), xantphos (0.037 g, 0.06 mmoles) and cesium carbonate (0.096 g, 0.30 mmoles) in a microwave reaction vessel. After bubbling nitrogen for 10 min. tris(dibenzylideneacetone)dipalladium (0.019 g, 0.02 mmoles) was added.
  • the mixture in the sealed vessel was irradiated to 150° C. for 1000 seconds.
  • the reaction mixture was filtered through syringe filter (Acrodisc CR25 mm with 0.2 ⁇ m PTFE membrane).
  • the vessel and filter were washed with ethyl acetate.
  • the combined organic layers were combined with filtrate and washed with brine, dried over sodium sulfate, filtered, concentrated in vacuo and the residue purified by flash chromatography (0-50% ethyl acetate/hexane) to afford the desired product (0.087 g, 85%).
  • Debenzylation using palladium on active carbon as previously described provided the title compound (0.056 g, 79%): MS (m/z): 398.2 [M+H] + .
  • Example 21 To a solution of 5-iodo-6-methyl-3-(2-phenylethyl)-2- ⁇ 2-[(phenylmethyl)oxy]phenyl ⁇ -4(3H)-pyrimidinone (0.20 g, 0.38 mmoles) of Example 21 in dioxane (5 mL) was added thiophene-3-boronic acid (0.098 g, 0.76 mmoles), 0.5 mL ethanol, and 0.5 mL aqueous sodium carbonate (0.081 g, 0.76 mmoles) in a microwave reaction vessel. After 10 min. of deoxygenation, tetrakis(triphenylphosphine)palladium (0.044 g, 0.04 mmoles) was added.
  • the mixture in sealed vessel was irradiated to 150° C. for 700 s.
  • the reaction mixture was filtered through syringe filter (Acrodisc CR25 mm with 0.2 ⁇ m PTFE membrane).
  • the vessel and filter were washed with ethyl acetate.
  • Example 66 The title compound was prepared according to the procedures of Example 66 except substituting 5-bromo-6-methyl-3-(2-phenylethyl)-2- ⁇ 2-[(phenylmethyl)oxy]phenyl ⁇ -4(3H)-pyrimidinone (example 20) for 5-iodo-6-methyl-3-(2-phenylethyl)-2- ⁇ 2-[(phenylmethyl)oxy]phenyl ⁇ -4(3H)-pyrimidinone and 4-trifluoromethylbenzeneboronic acid for thiophene-3-boronic acid provided the title compound: MS (m/z): 451.2 [M+H] + .
  • Example 66 The title compound was prepared according to the procedures of Example 66 except substituting 5-bromo-6-methyl-3-(2-phenylethyl)-2- ⁇ 2-[(phenylmethyl)oxy]phenyl ⁇ -4(3H)-pyrimidinone (example 20) for 5-iodo-6-methyl-3-(2-phenylethyl)-2- ⁇ 2-[(phenylmethyl)oxy]phenyl ⁇ -4(3H)-pyrimidinone and 3-fluorophenylboronic acid for thiophene-3-boronic acid: MS (m/z): 401.2 [M+H] + .
  • Example 66 The title compound was prepared according to the procedures of Example 66 except substituting 5-bromo-6-methyl-3-(2-phenylethyl)-2- ⁇ 2-[(phenylmethyl)oxy]phenyl ⁇ -4(3H)-pyrimidinone (example 20) for 5-iodo-6-methyl-3-(2-phenylethyl)-2- ⁇ 2-[(phenylmethyl)oxy]phenyl ⁇ -4(3H)-pyrimidinone and 2,4-difluorophenylboronic acid for thiophene-3-boronic acid: MS (m/z): 419.2 [M+H] + .
  • Example 11 To a solution of 5-bromo-2- ⁇ 3-fluoro-2-[(phenylmethyl)oxy]phenyl ⁇ -6-methyl-3-(2-phenylethyl)-4(3H)-pyrimidinone (0.20 g, 0.41 mmoles) of Example 11 in dioxane (5 mL) was added 4-(N,N-dimethylamino)phenylboronic acid (0.134 g, 0.81 mmoles), 0.5 mL ethanol, and 0.5 mL aqueous sodium carbonate (0.089 g, 0.81 mmoles) in a microwave reaction vessel. After 10 min.
  • the title compound was prepared according to the procedures of Example 74 except substituting 5-cyanothiophene-2-boronic acid for 4-(N,N-dimethylamino)phenylboronic acid and bis-(tri-t-butylphosphine)palladium for tetrakis(triphenylphosphine)palladium.
  • Microwave irradiation at 150° C. for 2400 seconds produced the desired compound.
  • Debenzylation using hydrobromic acid in acetic acid as previously detailed produced the title compound: MS (m/z): 432.2 [M+H] + .
  • Example 11 To a solution of 5-bromo-2- ⁇ 3-fluoro-2-[(phenylmethyl)oxy]phenyl ⁇ -6-methyl-3-(2-phenylethyl)-4(3H)-pyrimidinone (0.60 g, 1.2 mmoles) of Example 11 in dioxane was added N-Boc-pyrrole-2-boronic acid (0.51 g, 2.4 mmoles), 0.5 mL ethanol, and 0.5 mL aqueous sodium carbonate (0.26 g, 2.4 mmoles) in a microwave reaction vessel. After 10 min.
  • tetrakis(triphenylphosphine)palladium (0.14 g, 0.12 mmoles) was added.
  • the mixture in a sealed vessel was irradiated to 150° C. for 700 seconds.
  • the reaction mixture was filtered through syringe filter (Acrodisc CR25 mm with 0.20 ⁇ m PTFE membrane).
  • the vessel and filter were washed with ethyl acetate.
  • EtOAc combined with filtrate were washed with brine, separated, dried over sodium sulfate. Filtered, concentrated in vacuo and the residue was purified by flash chromatography to afford the title compound (0.285 g).
  • Example 13 The title compound was prepared following the general procedure outlined in Example 13 except substituting 5-bromo-6-methyl-3-(2-phenylethyl)-2- ⁇ 2-[(phenylmethyl)oxy]phenyl ⁇ 4(3H)-pyrimidinone of Example 20 for 5-bromo-2- ⁇ 3-fluoro-2-[(phenylmethyl)oxy]phenyl ⁇ -6-methyl-3-(2-phenylethyl)-4(3H)-pyrimidinone and 1,4-benzodioxane-6-boronic acid for quinoline-6-boronic acid. Subsequent deprotection using catalytic hydrogenolysis as previously detailed produced the final compound. MS (ES) m/e 441[M+H] + .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
US12/094,665 2005-11-22 2006-11-21 Calcilytic Compounds Abandoned US20090137557A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/094,665 US20090137557A1 (en) 2005-11-22 2006-11-21 Calcilytic Compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73873105P 2005-11-22 2005-11-22
US73906705P 2005-11-22 2005-11-22
US12/094,665 US20090137557A1 (en) 2005-11-22 2006-11-21 Calcilytic Compounds
PCT/US2006/061150 WO2007062370A2 (fr) 2005-11-22 2006-11-21 Composes calcilytiques

Publications (1)

Publication Number Publication Date
US20090137557A1 true US20090137557A1 (en) 2009-05-28

Family

ID=38068035

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/094,665 Abandoned US20090137557A1 (en) 2005-11-22 2006-11-21 Calcilytic Compounds

Country Status (14)

Country Link
US (1) US20090137557A1 (fr)
EP (1) EP1951244A4 (fr)
JP (1) JP2009516756A (fr)
KR (1) KR20080080136A (fr)
AR (1) AR057625A1 (fr)
AU (1) AU2006318275A1 (fr)
BR (1) BRPI0618900A2 (fr)
CA (1) CA2630117A1 (fr)
EA (1) EA200801414A1 (fr)
IL (1) IL191477A0 (fr)
MA (1) MA30042B1 (fr)
TW (1) TW200738649A (fr)
UY (1) UY29962A1 (fr)
WO (1) WO2007062370A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078778A2 (fr) * 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Nucléosides antiviraux contenant de l'azasucre
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
US10639302B2 (en) 2011-10-20 2020-05-05 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
CN118184502A (zh) * 2024-05-16 2024-06-14 济南悟通生物科技有限公司 一种制备藜芦酮的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
CN102015677A (zh) * 2007-04-20 2011-04-13 先灵公司 嘧啶酮衍生物及其使用方法
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
WO2010039913A1 (fr) * 2008-10-01 2010-04-08 Glaxosmithkline Llc Composé calcilytique
WO2010039922A1 (fr) * 2008-10-03 2010-04-08 Glaxosmithkline Llc Composés calcilytiques
FR2937321B1 (fr) * 2008-10-21 2010-10-22 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
US10183949B2 (en) 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107404A1 (en) * 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558260A4 (fr) * 2002-11-04 2006-10-25 Nps Pharma Inc Composes de quinazolinone utilises comme calcilytiques
WO2004092121A2 (fr) * 2003-04-07 2004-10-28 Nps Pharmaceuticals, Inc. Procedes pour preparer des 3h-pyrimidin-4-onessubstitues en 2,3,5,6
CA2549641A1 (fr) * 2003-12-19 2005-07-21 Merck & Co., Inc. Inhibiteurs mitotiques de la kinesine
WO2005060654A2 (fr) * 2003-12-19 2005-07-07 Merck & Co., Inc. Inhibiteurs de kinesines mitotiques
US20070232628A1 (en) * 2004-05-06 2007-10-04 Luengo Juan I Calcilytic Compounds
WO2006066070A2 (fr) * 2004-12-17 2006-06-22 Nps Pharmaceuticals, Inc. Constructions de promedicaments de composes de pyrimidinone utilises comme calcilytiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107404A1 (en) * 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10639302B2 (en) 2011-10-20 2020-05-05 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
US11351161B2 (en) 2011-10-20 2022-06-07 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
WO2014078778A2 (fr) * 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Nucléosides antiviraux contenant de l'azasucre
WO2014078778A3 (fr) * 2012-11-16 2014-10-09 Biocryst Pharmaceuticals, Inc. Nucléosides antiviraux contenant de l'azasucre
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
CN118184502A (zh) * 2024-05-16 2024-06-14 济南悟通生物科技有限公司 一种制备藜芦酮的方法

Also Published As

Publication number Publication date
JP2009516756A (ja) 2009-04-23
IL191477A0 (en) 2009-02-11
AU2006318275A1 (en) 2007-05-31
WO2007062370A3 (fr) 2007-11-22
UY29962A1 (es) 2007-06-29
WO2007062370A2 (fr) 2007-05-31
CA2630117A1 (fr) 2007-05-31
EP1951244A2 (fr) 2008-08-06
EP1951244A4 (fr) 2010-08-25
EA200801414A1 (ru) 2008-10-30
AR057625A1 (es) 2007-12-05
BRPI0618900A2 (pt) 2011-09-27
MA30042B1 (fr) 2008-12-01
KR20080080136A (ko) 2008-09-02
TW200738649A (en) 2007-10-16

Similar Documents

Publication Publication Date Title
US20090137557A1 (en) Calcilytic Compounds
US10738056B2 (en) Pyrazolopyrimidinone compounds and uses thereof
RU2417990C2 (ru) 2,6-замещенные-4-монозамещенный амино-пиримидины как антагонисты рецептора простагландина d2
TWI631124B (zh) 新穎胺基酸衍生物，其製備方法及含彼等之醫藥組合物
JP5857168B2 (ja) ドーパミンｄ１リガンドとしての複素芳香族化合物およびその使用
US6635638B2 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
US20080269298A1 (en) Benzimidazol-1-YL-thiophene compounds for the treatment of cancer
CA2729259A1 (fr) Composes heterocycliques a substitution en 1,2
US20100286152A1 (en) N-phenyl hydrazides as modulators of the ghrelin receptor
KR20090030321A (ko) 프롤릴 히드록실라제 억제제
JP2003502272A (ja) 神経ペプチドｙ受容体拮抗薬としての二環式ピリジンおよびピリミジン誘導体
WO2001062738A1 (fr) Composes a base d'imidazoline
JP2007514003A6 (ja) アデノシン受容体アンタゴニストとしての２，６−ビスヘテロアリール−４−アミノピリミジン
JP2007514003A (ja) アデノシン受容体アンタゴニストとしての２，６−ビスヘテロアリール−４−アミノピリミジン
AU2007264791A1 (en) Derivatives of ureas of piperidine or pyrrolidine, their preparation and their therapeutical use
JP2013514973A (ja) チロシンキナーゼ阻害剤
JP2017522277A (ja) 代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用
JP2010517967A (ja) 摂食障害の治療のための１−オキサ−３−アザスピロ［４，５］デカン−２−オン誘導体
JP2007519720A (ja) チアゾール化合物
TW200400965A (en) Antiviral compounds
JP2008510734A (ja) キナーゼ阻害剤
US9815796B2 (en) Pyrimidone carboxamide compounds as PDE2 inhibitors
MX2008006704A (en) Calcilytic compounds
TW200836742A (en) Benzoquinazoline derivatives
JP2003048875A (ja) １，２−エタンジアミン誘導体の製造法

Legal Events

Date Code Title Description
AS Assignment

Owner name: SMITHKLINE BEECHAM CORPORATION, PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KU, THOMAS WEN FU;LIN, HONG;LUENGO, JUAN I;AND OTHERS;REEL/FRAME:020983/0763;SIGNING DATES FROM 20070111 TO 20070112

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION